Skip to content
    Real-World Studies

    Lymphadenectomy During Interval Debulking Surgery for Advanced Epithelial Ovarian Cancer

    Liu et alInternational Journal of Women's Health

    In advanced epithelial ovarian cancer (AEOC) managed with neoadjuvant chemotherapy followed by interval debulking surgery (IDS), the clinical value of lymphadenectomy remains controversial. A multicenter retrospective real-world study across seven tertiary centers in China evaluated 1,068 patients treated between 2006 and 2021 to assess the procedure's impact on survival and perioperative safety. Among the full cohort, 528 patients (49.4%) underwent lymphadenectomy. To account for treatment selection bias, investigators utilized both propensity score matching (PSM; n = 960, with 480 patients per arm) and overlapping weight (OW; n = 1,068) analytical models.
    Across all cohorts, lymphadenectomy demonstrated a significant benefit in progression-free survival (PFS). The unadjusted model showed an HR of 0.77 (95% CI, 0.67–0.90; P = 0.001), which was preserved in the PSM cohort (HR, 0.77; 95% CI, 0.66–0.90; P = 0.001) and the OW cohort (HR, 0.76; 95% CI, 0.65–0.89; P = 0.001).
    Conversely, no significant difference was demonstrated for overall survival (OS). The absence of OS benefit persisted across unadjusted analyses (HR, 0.85; 95% CI, 0.70–1.02; P = 0.084), PSM-adjusted models (HR, 0.86; 95% CI, 0.70–1.05; P = 0.129), and OW-adjusted models (HR, 0.85; 95% CI, 0.70–1.03; P = 0.098).
    Regarding surgical safety, lymphadenectomy was not associated with higher rates of overall or severe postoperative complications across any model (all P > 0.05). The authors concluded that while lymphadenectomy during IDS improves PFS without compromising safety, prospective trials are necessary to validate these findings given the retrospective nature of the study design.

    Key Takeaways

    • Lymphadenectomy during interval debulking surgery was significantly associated with improved progression-free survival in propensity score-matched (HR, 0.77; 95% CI, 0.66–0.90; P = 0.001) and overlapping weight cohorts (HR, 0.76; 95% CI, 0.65–0.89; P = 0.001).
    • Overall survival was not significantly improved with lymphadenectomy following adjustment by propensity score matching (HR, 0.86; 95% CI, 0.70–1.05; P = 0.129) or overlapping weight analysis (HR, 0.85; 95% CI, 0.70–1.03; P = 0.098).
    • The addition of lymphadenectomy did not increase the incidence of overall or severe postoperative complications across all evaluated statistical models (all P > 0.05).
    Read the original sourceInternational Journal of Women's Health